Table 1.
Baseline characteristics of 1,982,488 subjects aged 18 years or older with baseline eGFR ≥60 ml/min per 1.73 m2 in different drug groups after weighting
| Characteristics | No Nonsteroidal Anti-Inflammatory Drug, n=1,734,701 | Nonsteroidal Anti-Inflammatory Drug, n=154,991 | Celecoxib, n=1274 | Etoricoxib, n=1030 | Diclofenac, n=90,829 | Ibuprofen, n=15,169 | Indomethacin, n=5199 | Mefenamic Acid, n=10,697 | Naproxen, n=28,966 | Piroxicam, n=1308 | Sulindac, n=519 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Men | 811,803 (47%) | 76,236 (49%) | 657 (52%) | 487 (47%) | 44,983 (50%) | 7486 (49%) | 2299 (44%) | 5157 (48%) | 14,221 (49%) | 719 (55%) | 230 (44%) |
| Age, yr | 55 (17) | 55 (16) | 55 (16) | 56 (16) | 55 (15) | 55 (16) | 55 (16) | 54 (17) | 55 (16) | 55 (14) | 56 (15) |
| Current smoker | 51,890 (3%) | 4813 (3%) | 29 (2%) | 26 (3%) | 2858 (3%) | 452 (3%) | 160 (3%) | 333 (3%) | 899 (3%) | 36 (3%) | 19 (4%) |
| Systolic BP, mm Hg | 132 (20) | 131 (20) | 130 (20) | 133 (21) | 131 (20) | 131 (20) | 132 (20) | 131 (20) | 131 (20) | 131 (20) | 131 (20) |
| Diastolic BP, mm Hg | 76 (12) | 76 (12) | 76 (12) | 77 (13) | 76 (12) | 76 (12) | 76 (12) | 76 (12) | 76 (12) | 76 (12) | 76 (12) |
| Fasting glucose, mg/dl | 102 (26) | 103 (27) | 101 (25) | 103 (29) | 103 (27) | 103 (28) | 103 (28) | 103 (29) | 103 (27) | 104 (28) | 103 (36) |
| BMI, kg/m2 | 24.5 (4.0) | 24.7 (4.0) | 24.4 (4.4) | 24.6 (4.4) | 24.7 (4.0) | 24.7 (4.0) | 24.8 (4.0) | 24.7 (4.2) | 24.7 (4.0) | 25.2 (3.9) | 24.4 (4.1) |
| LDL cholesterol, mg/dl | 117 (35) | 117 (35) | 116 (36) | 115 (34) | 117 (34) | 117 (35) | 117 (35) | 116 (36) | 117 (35) | 118 (35) | 118 (37) |
| eGFR, ml/min per 1.73 m2 | 113 (28) | 114 (27) | 116 (27) | 115 (26) | 114 (27) | 114 (28) | 115 (30) | 114 (27) | 114 (27) | 114 (27) | 115 (29) |
| Charlson comorbidity index | 2.4 (1.9) | 2.4 (1.8) | 2.4 (1.8) | 2.5 (1.9) | 2.4 (1.8) | 2.5 (1.8) | 2.5 (1.9) | 2.4 (1.9) | 2.4 (1.8) | 2.5 (1.7) | 2.6 (1.8) |
| Coronary heart disease | 80,730 (5%) | 7351 (5%) | 62 (5%) | 59 (6%) | 4261 (5%) | 704 (5%) | 227 (4%) | 564 (5%) | 1366 (5%) | 76 (6%) | 31 (6%) |
| Heart failure | 24,404 (1%) | 2162 (1%) | 16 (1%) | 13 (1%) | 1314 (1%) | 198 (1%) | 69 (1%) | 128 (1%) | 394 (1%) | 23 (2%) | 9 (2%) |
| Diabetes mellitus | 205,218 (12%) | 19,186 (12%) | 134 (11%) | 123 (12%) | 11,077 (12%) | 1856 (12%) | 659 (13%) | 1475 (14%) | 3605 (12%) | 190 (15%) | 64 (12%) |
| Atrial fibrillation | 31,443 (2%) | 2847 (2%) | 22 (2%) | 13 (1%) | 1744 (2%) | 267 (2%) | 94 (2%) | 137 (1%) | 534 (2%) | 26 (2%) | 11 (2%) |
| Peripheral vascular disease | 3928 (0.2%) | 549 (0.4%) | 1 (0.1%) | 5 (0.5%) | 316 (0.3%) | 46 (0.3%) | 21 (0.4%) | 55 (0.5%) | 93 (0.3%) | 10 (0.8%) | 1 (0.2%) |
| Stroke | 85,152 (5%) | 8133 (5%) | 54 (4%) | 64 (6%) | 4809 (5%) | 763 (5%) | 275 (5%) | 539 (5%) | 1522 (5%) | 84 (6%) | 23 (4%) |
| Amputation | 1725 (0.1%) | 176 (0.1%) | 3 (0.3%) | 4 (0.4%) | 92 (0.1%) | 19 (0.1%) | 4 (0.1%) | 15 (0.1%) | 36 (0.1%) | 3 (0.2%) | 0 (0%) |
| Dementia | 14,142 (0.8%) | 587 (0.4%) | 5 (0.4%) | 6 (0.6%) | 287 (0.3%) | 82 (0.5%) | 15 (0.3%) | 68 (0.6%) | 120 (0.4%) | 2 (0.2%) | 0 (0%) |
| Lung disease | 55,372 (3%) | 4989 (3%) | 37 (3%) | 33 (3%) | 2931 (3%) | 488 (3%) | 155 (3%) | 337 (3%) | 936 (3%) | 55 (4%) | 18 (3%) |
| Connective tissue disease | 4131 (0.2%) | 516 (0.3%) | 3 (0.2%) | 3 (0.3%) | 272 (0.3%) | 50 (0.3%) | 9 (0.2%) | 31 (0.3%) | 139 (0.5%) | 6 (0.4%) | 2 (0.4%) |
| Peptic ulcer | 38,341 (2%) | 3516 (2%) | 37 (3%) | 22 (2%) | 2049 (2%) | 329 (2%) | 123 (2%) | 253 (2%) | 649 (2%) | 45 (3%) | 10 (2%) |
| Liver disease | 41,312 (2%) | 3640 (2%) | 23 (2%) | 37 (4%) | 2158 (2%) | 351 (2%) | 116 (2%) | 251 (2%) | 664 (2%) | 25 (2%) | 15 (3%) |
| Hemiplegia | 7510 (0.4%) | 742 (0.5%) | 2 (0.1%) | 2 (0.2%) | 444 (0.5%) | 73 (0.5%) | 31 (0.6%) | 38 (0.4%) | 151 (0.5%) | 0 (0%) | 2 (0.4%) |
| Leukemia | 2244 (0.1%) | 112 (0.1%) | 2 (0.1%) | 0 (0%) | 43 (0%) | 26 (0.2%) | 6 (0.1%) | 15 (0.1%) | 20 (0.1%) | 0 (0%) | 0 (0%) |
| Malignant lymphoma | 2706 (0.2%) | 175 (0.1%) | 1 (0.1%) | 1 (0.1%) | 87 (0.1%) | 27 (0.2%) | 6 (0.1%) | 18 (0.2%) | 33 (0.1%) | 1 (0.1%) | 0 (0%) |
| Cancer | 95,455 (6%) | 8791 (6%) | 80 (6%) | 53 (5%) | 5004 (6%) | 830 (5%) | 300 (6%) | 864 (8%) | 1545 (5%) | 79 (6%) | 33 (6%) |
| Use of antidiabetic drugs | 207,087 (12%) | 19,217 (12%) | 136 (11%) | 125 (12%) | 11,090 (12%) | 1858 (12%) | 639 (12%) | 1536 (14%) | 3596 (12%) | 178 (14%) | 55 (11%) |
| Use of lipid-lowering agents | 184,958 (11%) | 16,640 (11%) | 121 (9%) | 104 (10%) | 9441 (10%) | 1634 (11%) | 555 (11%) | 1491 (14%) | 3076 (11%) | 157 (12%) | 55 (11%) |
| Use of antihypertensive drugs | 625,677 (36%) | 56,366 (36%) | 427 (33%) | 396 (38%) | 32,717 (36%) | 5455 (36%) | 1838 (35%) | 4421 (41%) | 10,409 (36%) | 508 (39%) | 186 (36%) |
| Use of aspirin | 178,623 (10%) | 16,147 (10%) | 127 (10%) | 143 (14%) | 9378 (10%) | 1617 (11%) | 526 (10%) | 1220 (11%) | 2933 (10%) | 148 (11%) | 55 (11%) |
All parameters are expressed in either number (percentage) or mean (SD). BMI, body mass index.